Matsuura Y, Kashimura M, Shinohara M, Baba S, Kondo M, Kashimura Y
Dept. of Obstetrics and Gynecology, Univ. of Occupational and Environmental Health, Japan.
Gan No Rinsho. 1990 Dec;36(15):2559-62.
In the management of a chorionic disease, human chorionic gonadotropin (hCG) is the most reliable tumor marker. However, hCG has a low titer, so that it cannot be strictly distinguished from the human luteinizing hormone (hLH) by the traditional method that uses a hemagglutinin reaction (HAR) or by a radioimmunoassay (RIA). Recently, however, the detection of the beta-COOH-terminal peptide of hCG (hCG-CTP) by an enzyme immunoassay has made it possible to clearly distinguish hCG from hLH, and from April, 1987 to December, 1989, 13 trophoblastic diseases have been managed using this new technique. Results have shown that human chorionic gonadotropin-CTP, when compared to other methods of measurement, is the most sensitive tumor marker and as it is the most accurate, it should be used in careful follow-up observations of a chorionic disease.
在绒毛膜疾病的管理中，人绒毛膜促性腺激素（hCG）是最可靠的肿瘤标志物。然而，hCG的滴度较低，因此通过使用血凝反应（HAR）的传统方法或放射免疫测定（RIA）无法将其与人类促黄体生成素（hLH）严格区分开来。然而，最近通过酶免疫测定法检测hCG的β-COOH末端肽（hCG-CTP）使得能够清楚地将hCG与hLH区分开来，并且从1987年4月到1989年12月，已经使用这种新技术管理了13例滋养层疾病。结果表明，与人绒毛膜促性腺激素-CTP相比，其他测量方法中，它是最敏感的肿瘤标志物，并且由于它最准确，应将其用于绒毛膜疾病的仔细随访观察中。
